The findings of this meta-analysis reveal that proper exposure to Corifollitropin alfa results in in-vitro fertilization (IVF) outcome comparable to that observed with recombinant FSH (rFSH).
- Corifollitropin alfa is a novel recombinant fertility hormone with prolonged follicle-stimulating activity used for controlled ovarian stimulation (COS) in IVF.
- It has a slower absorption and a longer elimination half-time in comparison to rFSH which is a unique feature.
- This meta analysis included 7 RCTs that enrolled a total of 3926 patients, of which 2138 women received Corifollitropin alfa and 1788 received daily rFSH.
- No significant difference was observed between Corifollitropin alfa and rFSH with respect to the majority of the clinical parameters but was comparable in terms of live birth rate, ongoing pregnancy rate, and clinical pregnancy rate.
- Major findings of the considered RCTs:
- The number of oocytes retrieved was not statistically different between the Corifollitropin alfa and rFSH groups.
- Pregnancies obtained in women undergoing COS with Corifollitropin alfa had the same risk of spontaneous abortion as pregnancies from rFSH.
- Considering ovarian response to COS, Corifollitropin alfa yielded a higher number of oocytes than rFSH.
Some of the women experienced cycle cancellation due to overstimulation, so it is important to carefully select the patients who are eligible for Corifollitropin alfa to prevent OHSS. Corifollitropin alfa thus, simplifies the treatment regimen in patients undergoing ovarian stimulation for IVF.